Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg (Record no. 75758)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04039cam a2200313 4500 |
| 001 - CONTROL NUMBER | |
| control field | NMDX6593 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 120401t2012 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 03057453 |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Okoli, C. |
| 240 ## - UNIFORM TITLE | |
| Uniform title | <a href="Journal of Antimicrobial Chemotherapy.">Journal of Antimicrobial Chemotherapy.</a> |
| 245 ## - TITLE STATEMENT | |
| Title | Once daily maraviroc 300mg or 150mg OD in combination with ritonavir -boosted darunavir 800/100mg |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Date of publication, distribution, etc. | 2012 |
| 500 ## - GENERAL NOTE | |
| General note | NMUH Staff Publications |
| 500 ## - GENERAL NOTE | |
| General note | 67 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | <br /><div style="line-height: 17.999801635742188px;"><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">OBJECTIVES:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">To describe the pharmacokinetics of maraviroc when dosed at 150 or 300 mg once daily with 800/100 mg of darunavir/ritonavir.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">METHODS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">A retrospective case-note review of HIV-infected adults taking maraviroc was conducted. Patients on a maraviroc-based regimen for a minimum of 5 weeks were grouped as receiving: (i) 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine; (ii) 300 mg of maraviroc once daily with 800/100 mg of darunavir/ritonavir once daily; and (iii) 150 mg of maraviroc once daily with 800/100 mg of darunavir/ritonavir once daily. C(trough) and C(peak) data were collected at 2, 12 or 24 h post-dose.</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">RESULTS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">Sixty-six patients were included, providing 115 samples. The median (IQR) C(peak) was 378 (350-640) ng/mL for 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine (n=9), 728 (378-935) ng/mL for 300 mg of maraviroc once daily with darunavir/ritonavir (n=29) and 364 (104-624) ng/mL for 150 mg of maraviroc once daily with darunavir/ritonavir (n=2; P=0.24). The median (IQR) C(trough) was 46 (33-61) ng/mL for 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine (n=12), 70 (49-97) ng/mL for 300 mg of maraviroc once daily with darunavir/ritonavir (n=34) and 43 (35-55) ng/mL for 150 mg of maraviroc once daily with darunavir/ritonavir (n=17; P=0.001). The maraviroc C(trough) in black patients (n=34) was 61 (45-110) ng/mL and in white patients (n=29) it was 49 (42-70) ng/mL (P=0.04). The C(peak) in black patients (n=20) was 800 (397-1060) ng/mL versus 387 (336-723) ng/mL in white patients (n=20; P=0.02).</span></p><h4 style="margin: 0px 0.25em 0px 0px; text-transform: uppercase; float: left;"><span style="font-size: 8pt;">CONCLUSIONS:</span></h4><p style="margin: 0px 0px 0.5em;"><span style="font-size: 8pt;">Once daily coadministration of 300 mg of maraviroc with 800/100 mg of darunavir/ritonavir was well tolerated and had favourable pharmacokinetics when compared with 300 mg of maraviroc twice daily with 245 mg of tenofovir/200 mg of emtricitabine. A 24% higher C(trough) and 107% higher C(peak) was seen in black patients compared with white patients.</span></p></div> |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Siccardi, M. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Thomas-William, S. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dufty, N. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Khonyongwa, K. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ainsworth, J. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Watson, J. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cook, R. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gandhi, K. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hickinbottom, G. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Owen, A. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Taylor S. |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Once+daily+maraviroc+300mg+or+150mg+OD+in+combination+with+ritonavir+-boosted+darunavir+800%2F100mg">http://www.ncbi.nlm.nih.gov/pubmed/?term=Once+daily+maraviroc+300mg+or+150mg+OD+in+combination+with+ritonavir+-boosted+darunavir+800%2F100mg</a> |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="http://jac.oxfordjournals.org/content/67/3/671.full.pdf+html">http://jac.oxfordjournals.org/content/67/3/671.full.pdf+html</a> |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection code | Home library | Current library | Shelving location | Date acquired | Total Checkouts | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Staff publications for NMDX | Ferriman information and Library Service (North Middlesex) | Ferriman information and Library Service (North Middlesex) | Shelves | 07/06/2022 | 07/06/2022 | 07/06/2022 | Book |